JOHN KIRKWOOD to Drug Resistance, Neoplasm
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Drug Resistance, Neoplasm.
Connection Strength
1.312
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.131
-
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. SLAS Discov. 2021 06; 26(5):712-729.
Score: 0.129
-
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
Score: 0.126
-
Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
Score: 0.125
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
Score: 0.122
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.089
-
Transcriptional repression of IFN?1 by ATF2 confers melanoma resistance to therapy. Oncogene. 2015 Nov 12; 34(46):5739-48.
Score: 0.087
-
PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
Score: 0.082
-
Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
Score: 0.082
-
Melanoma response and resistance - taking it to the tumor bank. Pigment Cell Melanoma Res. 2011 Oct; 24(5):978-9.
Score: 0.068
-
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010 Feb 01; 16(3):1042-8.
Score: 0.061
-
Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
Score: 0.053
-
Molecularly targeted therapy for melanoma: current reality and future options. Cancer. 2006 Nov 15; 107(10):2317-27.
Score: 0.049
-
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Mar 07; 8(10):16367-16386.
Score: 0.025
-
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
Score: 0.021
-
The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 09; 10:85.
Score: 0.018
-
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene. 2007 Jun 21; 26(29):4216-25.
Score: 0.012
-
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10; 24(29):4738-45.
Score: 0.012
-
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15; 177(4):2717-27.
Score: 0.012
-
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001; 19(1):89-92.
Score: 0.008